In this study, a [TIMP-2] × [IGFBP7] level greater than 2.0 (ng/mL)2/1000 measured nearly simultaneously with the assessment of AKI was associated with lower survival among patients at all 3 AKI stages but not among patients without AKI (stage 1S), although patients in this group had a longer median hospital LOS if their [TIMP-2] × [IGFBP7] level was greater than 2.0 (ng/mL)2/1000. The gene discussed is TIMP2; the disease is acute kidney injury.